Androgen receptor involvement in the progression of prostate cancer

Endocrine-Related Cancer

Volumn 10, Issue 2, 2003, Pages 209-216

  Suzuki, H ^a,b   Ueda, T ^a   Ichikawa, T ^a   Ito, H ^a  

^a CHIBA UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; CYTOSINE; DNA; ESTROGEN; FLUTAMIDE; GUANINE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NILUTAMIDE; PROGESTERONE; STEROID RECEPTOR COACTIVATOR 1;

ADAPTATION; AMINO TERMINAL SEQUENCE; CANCER INCIDENCE; CANCER STAGING; CELL LINE; CLONE; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE COURSE; DOWN REGULATION; DRUG TARGETING; GENE MUTATION; HORMONAL THERAPY; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; METHYLATION; NEGRO; NUCLEOTIDE REPEAT; PREDICTION; PROMOTER REGION; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN TARGETING; RACE DIFFERENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANDROGENS; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 0037599536     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0100209     Document Type: Conference Paper

References (38)

1. Balk SP 2002 Androgen receptor as a target in androgen-independent prostate cancer. Urology 60 132-138.
2. Baylin SB, Herman JG, Graff JR, Vertino PM & Issa JP 1998 Alterations in DNA methylation: a fundamental aspect of neoplasia. Advances in Cancer Research 72 141-196.
3. Craft N, Shostak Y, Carey M & Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine 5 280-285.
4. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G & Klocker H 1994 AR activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Research 54 5474-5478.
5. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M & Murphy GP 1999 Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41 127-133.
6. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ & Moul JW 1994 Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Research 54 2861-2864.
7. Gelmann EP 2002 Molecular biology of the androgen receptor. Journal of Clinical Oncology 20 3001-3015.
8. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS & Wilson EM 2001 A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Research 61 4315-4319.
9. Grossmann ME, Huang H & Tindall DJ 2001 Androgen receptor signaling in androgen-refractory prostate cancer. Journal of National Cancer Institute 93 1687-1697.
10. Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, Nanus DM et al. 1996 Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. Journal of Clinical Endocrinology and Metabolism 81 4400-4405.
11. Kelly WK & Scher HI 1993 Prostate specific antiandrogen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. Journal of Urology 149 607-609.
12. Kokontis JM & Liao S 1999 Molecular action of androgen in the normal and neoplastic prostate. Vitamins and Hormones 55 219-307.
13. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L et al. 2000 Androgen receptor mutations in prostate cancer. Cancer Research 60 944-949.
14. Masai M, Sumiya H, Akimoto S, Yatani R, Chang CS, Liao SS & Shimazaki J 1990 Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 17 293-300.
15. Montgomery JS, Price DK & Figg WD 2001 The androgen receptor gene and its influence on the development and progression of prostate cancer. Journal of Pathology 195 138-146.
16. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H & Murai M 2000 Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clinical Cancer Research 6 2702-2706.
17. Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa Y, Mizokami A, Ito H, Yatani R & Shiraishi T 2000 Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Laboratory Investigation 80 1789-1796.
18. Nakayama T, Watanabe M, Yamanaka M, Yoshifumi H, Suzuki H, Ito H, Yatani R & Shiraishi T 2001 The role of epigenetic modifications in retinoic acid receptor β2 gene expression in human prostate cancers. Laboratory Investigation 81 1049-1057.
19. Navarro D, Luzardo OP, Fernandez L, Chesa N & Diaz-Chico BN 2002 Transition to androgen-independence in prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 81 191-201.
20. Okamoto M, Lee C & Oyasu R 1997 Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Research 57 141-146.
21. Onate SA, Tsai SY, Tsai MJ & O'Malley BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270 1354-1357.
22. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP & Visakorpi T 2000 Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. Journal of Urology 164 1992-1995.
23. Rowan BG, Garrison N, Weigel NL & O'Malley BW 2000 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Molecular and Cellular Biology 20 8720-8730.
24. Sadar MD 1999 Androgen-independent induction of prostate specific antigen gene expression via cross-talk between the androgen receptor and PKA signal transduction pathways. Journal of Biological Chemistry 274 7777-7783.
25. Suzuki H, Sato N, Watabe Y, Seino S & Shimazaki J 1993 Androgen receptor gene mutations in human prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 46 759-765.
26. Suzuki H, Nihei N, Sato N, Ichikawa T, Mizokami A & Shimazaki J 1994 Inhibition of growth and increase of acid phosphatase by testosterone on androgen-independent murine prostatic cancer cells transfected with androgen receptor cDNA. Prostate 25 310-319.
27. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S & Shimazaki J 1996 Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29 153-158.
28. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D et al. 1998 Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Research 58 204-209.
29. Suzuki H, Akakura K, Komiya A, Ueda T, Imamoto T, Furuya Y, Ichikawa T, Watanabe M, Shiraishi T & Ito H 2002 CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy. Prostate 51 219-224.
30. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R & Shimazaki J 1996 Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 77 934-940.
31. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK et al. 1995 Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New England Journal of Medicine 332 1393-1398.
32. Taplin ME, Bubley GJ, Ko Y-J, Small EJ, Barur U, Rajeshkumar B et al. 1999 Selection for androgen receptor mutations in prostate cancer treated with androgen antagonist. Cancer Research 59 2511-2515.
33. Ueda T, Bruchovsky N & Sadar M 2002 Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. Journal of Biological Chemistry 277 7076-7085.
34. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E et al. 1990 A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochemical and Biophysical Research Communications 173 534-540.
35. Visakorpi T, Hyytinen ER, Koivisto P, Tanner M, Keinßnen R, Palmberg C et al. 1995 In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 9 401-406.
36. Webb P, Ngugen P, Shinkako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E, Katzenellenbogen BS, Stallcup MR & Kushner PJ 1998 Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Molecular Endocrinology 12 1605-1618.
37. Yeh S & Chang C 1996 Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. PNAS 93 5517-5521.
38. Zilliacus J, Wright APH, Carlstedt-Duke J & Gustafsson JA 1995 Structural determinants of DNA-binding specificity by steroid receptors. Molecular Endocrinology 9 389-400.